Tumor necrosis factor receptor p55 and p75 deficiency protects mice from developing experimental autoimmune myasthenia gravis

Journal of Neuroimmunology

Volumn 122, Issue 1-2, 2002, Pages 85-93

  Goluszko, Elzbieta ^a   Deng, Caishu ^a   Poussin, Mathilde A ^a   Christadoss, Premkumar ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Autoimmunity; Lymphotoxin ; Myasthenia gravis; TNF receptors; TNF

Indexed keywords

CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN M; PROTEIN P55; PROTEIN P75; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; EXPERIMENTAL MOUSE; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN GENE; MOUSE; MYASTHENIA GRAVIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEFICIENCY;

ANIMALS; ANTIGENS, CD; FEMALE; GENETIC PREDISPOSITION TO DISEASE; IMMUNIZATION; IMMUNOGLOBULIN CLASS SWITCHING; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LYMPHOCYTES; LYMPHOTOXIN-ALPHA; MALE; MICE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MUSCLE, SKELETAL; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; RECEPTORS, CHOLINERGIC; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036147552     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(01)00474-X     Document Type: Article

References (62)

1. Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice
2. Tumour necrosis factor-alpha (TNF-alpha): The good, the bad and potentially very effective
3. Unraveling function in the TNF ligand and receptor families
4. T-cell tumor necrosis factor-alpha receptor binding in myasthenic patients
5. Cytokine regulation of secondary lymphoid organ development
6. Immunotherapy for myasthenia gravis: A murine model
7. Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor Fc protein
8. Genetic control of experimental autoimmune myasthenia gravis in mice: I. Lymphocyte proliferative response to acetylcholine receptors is under H-2-linked Ir gene control
9. Genetic control of autoimmunity to acetylcholine receptors: Role of Ia molecules
10. Genetic control of experimental autoimmune myasthenia gravis in mice: III. Ia molecules mediate cellular immune responsiveness to acetylcholine receptors
11. Muscle acetylcholine receptor loss in murine experimental autoimmune myasthenia gravis: Correlated with cellular, humoral and clinical responses
12. IFN-alpha therapy is effective in suppressing the clinical experimental myasthenia gravis
13. Fas/fas ligand pathway, apoptosis, and clonal anergy involved in systemic acetylcholine receptor T cell epitope tolerance
14. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin
15. Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina
16. Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis
17. Myasthenia gravis
18. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
19. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice
20. Effects of tumor necrosis factor and lymphotoxin on peripheral lymphoid tissue development
21. Neuromuscular junction in myasthenia gravis: Decreased acetylcholine receptors
22. Tumor necrosis factor (TNF) microsatellite haplotypes in relation to extended haplotypes, susceptibility to diseases associated with the major histocompatibility complex and TNF secretion
23. Constitutive synthesis of tumor necrosis factor in the thymus
24. Lymphotoxin-alpha deficiency completely protects C57BL/6 mice from developing clinical experimental autoimmune myasthenia gravis
25. Polymorphism in tumor necrosis factor genes associated with myasthenia gravis
26. Myasthenia gravis muscle antibodies examined by ELISA: IgG and IgM antibodies characterize different patient subgroups
27. The role of the thymus in myasthenia gravis
28. Tumour necrosis factor-alpha polymorphism and secretion in myasthenia gravis
29. Prevention of autoimmune diabetes mellitus in NOD mice by transgenic expression of soluble tumor necrosis factor receptor p55
30. Isotype-specific regulation of MHC class II gene expression in human monocytes by exogenous and endogenous tumor necrosis factor
31. Enhancement of human B cell proliferation and differentiation by tumor necrosis factor-alpha and interleukin 1
32. Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis
33. Effect of tumor necrosis factor alpha on mitogen-activated human B cells
34. Production and assay of antibodies to acetylcholine receptors
35. Interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in multiple sclerosis and myasthenia gravis
36. TNF blockade in rheumatoid arthritis: Implications for therapy and pathogenesis
37. Role of lymphotoxin and the type I TNF receptor in the formation of germinal centers
38. Lymphotoxin-alpha-deficient and TNF receptor-I-deficient mice define developmental and functional characteristics of germinal centers
39. Tumor necrosis factor-alpha, lymphotoxin, interleukin (IL)-6, IL-10, IL-12 and perforin mRNA expression in mononuclear cells in response to acetylcholine receptor is augmented in myasthenia gravis
40. IL-12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody-mediated disease
41. TNF receptor-deficient mice reveal striking differences between several models of thymocyte negative selection
42. Immune and inflammatory responses in TNF alpha-deficient mice: A critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response
43. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation
44. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection
45. Suppression of experimental autoimmune myasthenia gravis in IL-10 gene-disrupted mice is associated with reduced B cells and serum cytotoxicity on mouse cell line expressing AChR
46. HLA class II induction in human islet cells by interferon-gamma plus tumour necrosis factor or lymphotoxin
47. Antiviral activity of tumor necrosis factor (TNF) is mediated via p55 and p75 TNF receptors
48. Experimental autoimmune encephalomyelitis: Immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors
49. In vivo relationship of tumor necrosis factor-alpha to blood-brain barrier damage in patients with active multiple sclerosis
50. Natural killer cells determine the outcome of B cell-mediated autoimmunity
51. Failure to down-regulate Bcl-2 protein in thymic germinal center B cells in myasthenia gravis
52. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus
53. Production of tumor necrosis factor/cachectin by human T cell lines and peripheral blood T lymphocytes stimulated by phorbol myristate acetate and anti-CD3 antibody
54. The pathophysiology of tumor necrosis factors
55. In-vitro synthesis of anti-acetylcholine-receptor antibody by thymic lymphocytes in myasthenia gravis
56. Tumor necrosis factor receptor-1 is critically involved in the development of experimental autoimmune myasthenia gravis
57. Tumor necrosis factor (TNF) receptor expression in T lymphocytes. Differential regulation of the type I TNF receptor during activation of resting and effector T cells
58. Regulation of MHC class II antigen expression. Opposing effects of tumor necrosis factor-alpha on IFN-gamma-induced HLA-DR and Ia expression depends on the maturation and differentiation stage of the cell
59. Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4
60. Tolerance to a dominant T cell epitope in the acetylcholine receptor molecule induces epitope spread and suppresses murine myasthenia gravis
61. Experimental autoimmune myasthenia gravis in the mouse
62. Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis